October 3, 2025Press Release
Preclinical Proof-of-Concept Announced
Ironfist Therapeutics announces preclinical proof-of-concept for novel nanomedicine radiopharmaceutical Tamrada™.
Read more
Novel Cancer Immunotherapy
Transforming TAMs from Accomplices to Targets
Developing TAM-targeted radiopharmaceuticals that dismantle the tumor's protective microenvironment and re-awaken immune recognition.
Approach
TAM-Targeted
Platform
Hydroxyl Dendrimer
Lead Program
Tamrada™
The Science
A novel approach to targeting the tumor microenvironment through TAM-directed radiopharmaceuticals
The Challenge
TAMs Shield Tumors from Immune Attack
Tumor-associated macrophages (TAMs) create an immunosuppressive microenvironment that allows cancer to evade the immune system and resist conventional therapies.
- Promote tumor growth and metastasis
- Suppress anti-tumor immunity
- Drive resistance to standard treatments
Our Solution
Precision Radiopharmaceuticals Target TAMs
Our platform combines targeted delivery with therapeutic radioisotopes to selectively eliminate TAMs, restoring anti-tumor immunity.
- Selectively binds to TAM surface markers
- Delivers localized radiation to eliminate TAMs
- Restores immune system function
Understanding TAM-Targeted Therapy
Target Recognition
Our compounds specifically recognize and bind to markers expressed on tumor-associated macrophages.
Selective Delivery
Radioisotopes are delivered precisely to TAMs in the tumor microenvironment, minimizing off-target effects.
Immune Restoration
Eliminating TAMs restores the tumor microenvironment, enabling the immune system to attack cancer cells.
Clinical Advantages
Targeted
Precision delivery to TAMs
Systemic
Treats primary & metastatic disease
Combinable
Works with other therapies
Novel
First-in-class approach
Pipeline
Advancing a platform that redefines macrophage-directed therapy
Lead Program
Tamrada™
Our lead TAM-targeted radiopharmaceutical designed to deliver 177Lu radionuclides to immunosuppressive macrophages in the tumor microenvironment.
Key Differentiators
Selective Targeting
Specific accumulation in TAMs
Immune Reactivation
Restores anti-tumor immunity
Broad Applicability
Across solid tumor types
Durable Response
Long-lasting therapeutic effect
Current Stage
Preclinical
Target Indication
Solid Tumors Resistant to Immunotherapies
Milestone
Proof of Concept Achieved
Development Timeline
Preclinical Studies
CompletedDemonstrated selective TAM targeting and proof of concept
IND-Enabling Studies
In ProgressAdvancing toward regulatory submission
Phase I Clinical Trial
PlannedFirst-in-human safety and efficacy evaluation
Platform Expansion
Several radiopharmaceutical products with a wide range of isotopes are enabled with this technology.
News & Updates
Latest developments and milestones in our journey